autologous tumor-infiltrating lymphocytes + pd-1 antibody

This is a **combination therapy** consisting of *autologous tumor-infiltrating lymphocytes (TILs)* and a *PD-1 antibody*. TILs are expanded ex vivo from a patient's own tumor tissue and infused to attack cancer cells, while PD-1 antibodies (such as nivolumab) function as immune checkpoint inhibitors to block PD-1 and enhance the anti-tumor activity of T cells. The mechanism involves direct cytotoxicity against tumor cells by TILs, augmented by the PD-1 antibody which prevents exhaustion of T cells and maintains their activity in the tumor microenvironment. This combination has been investigated primarily for advanced/metastatic solid tumors, notably melanoma and non-small cell lung cancer, with the PD-1 antibody most commonly used being nivolumab. The therapy typically includes lymphodepletion and administration of IL-2, with maintenance PD-1 blockade following TIL infusion. Key clinical outcomes include increased objective response rates and potential for complete responses even in checkpoint-resistant disease[1][2][3][4].

Other names

autologous TIL + PD-1 antibodyTIL + PD-1 inhibitoradoptive TIL + checkpoint inhibitor